Rheumatoid arthritis Flashcards

1
Q

In what age range does RA most commonly develop?

A

25-50 years old

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the difference in prevalence of RA in men and women?

A

RA is more common in women- the ratio of cases of men to women in 2-3:1

  • around 1.5 men and 3.6 women developing RA per 10,000 people per year in the UK
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What percentage of the UK population have RA?

A

1%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the causes of rheumatoid arthritis?

A

Is though to be multi-factorial, but causes aren’t exactly known:

  • Genetic predisposition- 70% of patients express the human leukocyte antigen, HLA-DR4
  • Other genes are also though to be involved including STAT4, TRAF1/C5 and PTPN22, MHC allele HLA-DRB1
  • Environmental factors- occupational exposure e.g. oil or silicas, tobacco smoke, air pollution
  • Smoking
  • Autoimmunity, including antibodies such as anti-citrullinated peptide antibodies (ACPAs) and rheumatoid factors (RFs), is associated with RA
  • Hormones- more common in women
  • Infection- multiple viruses have been suggested to link to RA but haven’t been proven e.g. Epstein-Barr virus, streptococcus and parvovirus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What type of condition is rheumatoid arthritis?

A

A systemic autoimmune disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the stages of rheumatoid arthritis?

A
  • INITIATOR PHASE:
    The initiating event is unknown and reason for joint specific localisation is unknown.
    It could be due to injury, infection, exposure to toxic substances
  • The antigen-presenting cells and citrillination of proteins are now seen as non-self.
  • INFLAMMATION PHASE:
    Self-antigens are presented which causes an immune reaction; clonal expansion of t and b-cells = proliferate
    There is insufficient control by T-regulatory cells, so t and b-cells are activated in the joint (we don’t want them to be activated here) = tissue damage. B-cells produce autoantibodies e.g. Rheumatoid factor (RF) and anti-citrullinated peptides- which can activate the complement system and also can bind to activated macrophages in the synovium= prolong inflammation indefinitely. T-cell can activate monocytes, macrophages and fibroblasts = production of cytokines e.g. TNF alpha, IL-6, IL-1= these induce MMP production= MMPs degrade cartilage. (ALL CONNECT TO DESTRUCTION PHASE BELOW??)
  • SELF-PERPETUATING PHASE:
    The inflammatory damage in the synovial means that self-antigens previously ‘unseen’ by the immune system become exposed. This causes an immune response against cartilage and there is an infiltration of immune cells. This doesn’t go back to resolution
  • DESTRUCTION PHASE:
    Cytokines such as TNF, IL-6 activate the synovial fibroblasts and osteoclasts (resorb/degrade bone). This leads to the bone and cartilage being destroyed. Also, the RANK ligand can promote osteoclasts to resorb the bone.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are examples of the co-morbidities associated with RA, that can be caused due to circulating inflammatory mediators e.g. cytokines?

A
  • TNF-𝛼 : Insulin resistance in muscle, free fatty acid, atherosclerosis of blood vessels that can leas to MI or stroke, low mineral bone density= fractures
  • IL-6: Blood vessel, fat as above. + impacts on the acute-phase response in the liver and low stress tolerance in the brain= depression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the symptoms of RA?

A

Symptoms usually have an insidious onset (gradual):
- Pain, swelling, redness and stiffness most commonly of the small synovial joints of the hands, wrists, and feet
- Pain and stiffness is usually worse after rest/sleeping. Morning stiffness should last longer than 30 minutes- or could be a sign of osteoarthritis
- May also present with fever, malaise, weakness, weight loss, poor appetite
- May have RA nodules- subcutaneous lumps around the joints
- May also affect other areas of the body e.g. the eyes or chest

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Discuss the general progress of RA symptoms over time?

A
  • Often starts with the insidious onset of a fever, malaise or weakness and pain in the joints
  • This then leads to inflammation in the synovial joints usually in the hands, wrists and feet. This presents as pain, tenderness, swelling, stiffness, redness or warmth
  • Overtime, can cause progressive articular deterioration (loss of function):
    Inflammation
    Destruction of bone and cartilage
    Deformity in joint
    Limited motion/pain on motion
    can also cause weight loss, Low mental health, fatigue at this stage.
    Can then go on to affect other organs e.g. lungs (pulmonary fibrosis), Heart (cardiovascular disease), Eyes, skin and bone
  • In 20% of patients, they develop rheumatoid nodules- firm lumps that appear subcutaneously under the skin. often where the joints under the most trauma. The incidence of patients developing these is decreasing nowadays due to the development of RA treatments.
  • Usually patients will have exacerbations and flare ups and then periods of remission. overtime, chronic progression and deterioration is likely.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the clinical course of RA?

A

Usually patients will have exacerbations and flare ups and then periods of remission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the possible co-morbidities of RA?

A
  • Increased cardiovascular risk
  • Increased infection risk
  • Respiratory problems
  • Osteoporosis
  • Malignancy- cancers such as lung and lymphomas
  • Depression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How is rheumatoid arthritis diagnosed?

A

NO ONE TEST PROVIDES A RA DIAGNOSIS

BLOOD TESTS-
Inflammatory markers:

  • Erythrocyte sedimentation rate (ESR)- Alerts us on the degree of inflammation within the joints. The higher the rate, the more inflammation is present
  • C-reactive protein (CRP)- A protein that is produced in the liver as part of the innate immune response.
    (NOTE- both of these 2 can be increased due to other inflammation/surgery)

Immunological parameters:
- Rheumatoid factor (RF)- an autoantibody that is found in 70% of RA patients. But it is not specific enough for RA or essential for diagnosis
- Anti-nuclear antibody (ANA)- Autoantibody in 40% of RA patients
- Anti-cyclic citrullinated peptide (Anti-ccp)- Autoantibody against cytrilline

HAEMATOLOGY

RADIOLOGY: Looks at the damage and inflammation within the joints ( this is not always visable on x-rays)

EXAMINATION:
- LIMITED MOTION TEST- the patient finds it hard to form a tight fist
- METACARPOPHALANGEAL (hand) OR METATARSOPHALANGEAL (feet) SQUEEZE: Squeeze the knuckle joints. If the patient has RA, it would feel gel-like at the joints and would be very painful- undue pain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the difference between the metocarpophalangeal squeeze and the metatarsophalangeal squeeze?

A

Metocarpophalangeal = squeezing the hands metatarsophalangeal = squeezing the feet

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the inflammatory markers associated with RA?

A
  • Erythrocyte sedimentation rate (ESR)- Alerts us on the degree of inflammation within the joints. The higher the rate, the more inflammation is present
  • C-reactive protein (CRP)- A protein that is produced in the liver as part of the innate immune response.
    (NOTE- both of these 2 can be increased due to other inflammation/surgery)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the immunological markers associated with RA?

A
  • Rheumatoid factor (RF)- an autoantibody that is found in 70% of RA patients. But it is not specific enough for RA or essential for diagnosis
  • Anti-nuclear antibody (ANA)- Autoantibody in 40% of RA patients
  • Anti-cyclic citrullinated peptide (Anti-ccp)- Autoantibody against cytrilline
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What does it mean if a RA patient is sero-positive?

A

if their blood tests are positive for autoantibodies- Rheumatoid factor and/or Anti-CCP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What guidelines are used in the management of rheumatoid arthritis?

A

NICE 2018- Rheumatoid arthritis in adults: management
+
EULAR- European league against rheumatism (2019)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

When does a patient need to be referred from primary care to secondary care when presenting to a GP with RA symptoms?

A

If suspected synovitis (inflammation of synovial membrane)
Should be urgent if:
- Is affecting the small joints in the hand or feet
- if more than one joint is affected
- If the patient has waited more than 3 months before seeking medical attention

(even with a normal acute-phase response, negative anti-cyclic citrullinated peptide [CCP] antibodies or rheumatoid factor)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the diagnostic process should a patient have synovitis (swelling of the joints) on a clinical examination?

A

Do a blood test:
- look for rheumatoid factor
- If is negative for RF, test for anti-ccp antibodies

  • x-ray the hands and feet
  • health assessment questionnaire (HAQ)- looks at the patients functional ability, disability, pain, drug side effects and toxicity, costs etc
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the DAS28 score?

A

The DAS28 (DAS= disease activity score) score is a measure of the disease activity in RA. Allows for disease and treatment monitoring.
- It measures 28 joints as part of the assessment
- Provides a score between 0 and 10

21
Q

What 4 components does the DAS28 score look at?

A
  • The number of swollen joints (out of 28)
  • The number of tender joints (out of 28)
  • Measure of ESR or CRP (From a blood test)
  • ‘Global assessment of health’ score
22
Q

What are the classes of scores of DAS28 and what do they indicate?

A

> 5.1 = active disease
<3.2 = low disease activity
<2.6 = Disease remission

23
Q

How many joints does the DAS28 score assess?

A

28

24
Q

What are the weaknesses of the DAS28 scoring system for monitoring RA?

A
  • It doesn’t incorporate any of the joints in the feet in the 28 joints
  • Not all patients have an affected ESR or CRP
25
Q

What does Erythrocyte sedimentation rate (ESR) tell us?

A

Alerts us on the degree of inflammation within the joints. The higher the rate, the more inflammation is present

26
Q

What does a C-reactive protein (CRP) result tell us?

A
  • C-reactive protein (CRP)- is a protein that is produced in the liver as part of the innate immune response. So shows us extent of inflammation.
27
Q

What percentage of RA patients have Rheumatoid factor (RF)?

A
  • Rheumatoid factor (RF)- an autoantibody that is found in 70% of RA patients.
28
Q

Can rheumatoid factor alone be used for diagnosis?

A

no as it is not specific enough for RA or essential for a diagnosis

Not all people with RA test positive for RF; some people test positive for RF but never develop the disease; and some people test positive but have another disease

29
Q

What are the aims of treatment in RA?

A
  • Minimise joint pain and swelling
  • prevent deformity and radiological damage
  • Maintain quality of life
  • prevent/control extra-articular manifestations
30
Q

What is the first line treatment following a RA diagnosis?

A

Offer first line treatment with a oral conventional disease modifying anti-rheumatic drug (cDMARD), Either: (none is better than the the others)
- Methotrexate
- Leflunomide
- Sulfasalazine

Consider Hydroxychloroquine for mild or palindromic disease

May consider short-term bridging with a Glucocorticoid when starting a cDMARD in patients with a more active condition:
A short course of steroids e.g. Prednisolone which will give anti-inflammatory effects until the cDMARD is working fully ( takes time to decrease the symptoms). Remove within 3 months MAX.

31
Q

What is the first recommendation that should be made following a RA diagnosis?

A

Must recommend that patients INCREASE THEIR EXERCISE LEVELS.

32
Q

What does it mean that the RA treatment guidelines aim to ‘Treat to target’?

A

Patients will have frequent reviews and monitoring, if inflammation is still present then treatment is escalated until good control is reached.
Each patient will have an individual target :
Remission = DAS 28 <2.6
Low activity = DAS 28 <3.2

33
Q

What DAS28 score is indicative of remission and of low activity?

A

Remission = <2.6
Low activity = <3.2

34
Q

When/why may a patient be started on a steroid as part of their management?

A

May consider short-term bridging with a Glucocorticoid in patients starting a cDMARD treatment if they have a in more active condition:
A short course of steroids e.g. Prednisolone which will give anti-inflammatory effects until the cDMARD is working fully ( takes time to decrease the symptoms). Remove within 3 months MAX.

35
Q

What is the step-up therapy after a patient has started a cDMARD?

A

If a cDMARD therapy is ineffective even when dose has been optimised, offer an additional cDMARD.
+ methotrexate, Sulphasalazine, Leflunomide or Hydroxychloroquine

36
Q

What is the next step in treatment if step 1 is insufficient?

A

Step-up strategy: Adding of an additional cDMARD when the optimised dose of a singular cDMARD is inadequate.
+ methotrexate, Sulphasalazine, Leflunomide or Hydroxychloroquine

37
Q

If the first line treatment and step-up strategy is inadequate and treating to target, what is the next step?

A

The next treatment option is dependent on whether the patient has moderate (DAS 3.2-5.1) or severe disease (DAS >5.1):

  • Would add a biological DMARD (bDMARD)
    e.g.
    MODERATE:
  • Anti-TNF (-mab) e.g. Adalinumab, Etanercept or infliximab (infliximab has to be given with methotrexate)
  • Trgeted tDMARDS e.g JAK inhibitors such as Fligotinib or Upadatacitinib (more expensive)
  • antibody blocking t-cell activation e.g. Abatacept

SEVERE:
- Anti-TNF (-mab) e.g. Adalinumab, Etanercept, infliximab, Certolizumab, golisumab
- Targeted tDMARDS e.g JAK inhibitors such as Fligotinib or Upadatacitinib, Baricitinib, Tofactitinib
- antibody blocking t-cell activation e.g. Abatacept
- Anti IL-6 e.g. Sarilumab, Tocilizumab
- Anti B-cell e.g. Rituximab

38
Q

What must the patients response to a bDMARD be to continue taking it?

A

The patient must have had a moderate response at 6 months to continue:
If have moderate disease: DAS28 improvement of >0.6 and <1.2
If have severe disease:
DAS28 improvement of >1.2

39
Q

What treatment would be given to a patient incase of a flare up?

A
  • Short term treatment with glucocorticoids.
40
Q

What does the ‘Step down’ strategy involve?

A

If patients have been maintained on their current treatment for 1 year without any use of steroids for a flare up:
- their maintenance drug dose may be cautiously decreased
or
- if they are on multiple drugs, 1 may be stopped

If this however causes a flare up, need to contact rheumatology and give a short course of steroids and return to previous DMARD regime.

41
Q

What is the procedure should the ‘step down’ strategy lead to a flare up?

A

If this however causes a flare up, need to contact rheumatology and give a short course of steroids and return to previous DMARD regime.

42
Q

What treatment can be used for symptom control in RA?

A

If pain and stiffness is uncontrolled, consider traditional NSAIDs or COX II inhibitors (still NSAIDS, just more selective)

  • Should consider any potential toxicities e.g. GI, Cardio, renal, liver and any risk factors e.g. pregnancy and age

When using oral NSAIDs:
- Offer the lowest effective dose for the shortest possible time
- Offer a proton pump inhibitor (PPI) to decrease GI effects
- Review risk factors for adverse events regularly

43
Q

When prescribing NSAIDs for symptom control in RA, what other drug should be prescribed?

A

A proton pump inhibitor (PPI) to reduce GI effects

44
Q

If a patient needs to take low-dose aspirin for another condition, should NSAIDs be used for pain relief?

A

Other treatment should be considered before adding an NSAID

45
Q

What non-pharmacological management should be recommended for patients with RA?

A
  • Improve general fitness and encourage regular exercise
  • Learn exercised for enhancing joint flexibility and muscle strength
  • consider short term pain relief mechanisms e.g TENS machines
  • offer access to an occupational therapist- for help with everyday activities or problems with hand functioning
  • Access to a podiatrist
46
Q

What is the purpose of an annual review for RA patients and what does it involve?

A
  • Check functional ability and disease damage- Health assessment questionnaire
  • Check or development of any co-morbidities e.g. HT, IHD, osteoporosis, depression
  • Assess for any complications e.g. disease of the lung or eyes
  • organise any appropriate referrals to other parts of the MDT
  • Assess any need for surgery
47
Q

When may an appointment be schedule for a RA patient in 6 months time?

A

Consider a review appointment to take place 6 months after achieving treatment target (remission or low disease activity) to ensure that the target has been maintained

48
Q

What are the 2 main differences between the NICE and the EULAR guidelines?

A
  • EULAR recommends tDMARDs as before or equal to bDMARDs. NICE recommends bDMARDs use first
  • NICE doesn’t recommend methotrexate over leflunomide or sulphasalazine, but EULAR recommends methotrexate first line and preferable to sulphasalazine or leflunomide